TSHA Stock Summary and Trading Ideas (Taysha Gene Therapies | NASDAQ:TSHA)

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Taysha Gene Therapies trades on the NASDAQ stock market under the symbol TSHA.

As of January 9, 2026, TSHA stock price declined to $4.98 with 2,937,931 million shares trading.

TSHA has a beta of 2.75, meaning it tends to be more sensitive to market movements. TSHA has a correlation of 0.23 to the broad based SPY ETF.

TSHA has a market cap of $1.36 billion. This is considered a Small Cap stock.

Last quarter Taysha Gene Therapies reported $0 in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-1 million and met earnings estimates .

In the last 3 years, TSHA traded as high as $6.02 and as low as $.50.

The top ETF exchange traded funds that TSHA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

TSHA has outperformed the market in the last year with a return of +158.0%, while the SPY ETF gained +19.0%. However, in the most recent history, TSHA shares have underperformed the stock market with its stock returning -0.4% in the last 3 month period and -14.6% for the last 2 week period, while SPY has returned +3.7% and +0.5%, respectively.

TSHA support price is $4.90 and resistance is $5.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TSHA shares will trade within this expected range on the day.